We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+41.42%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$70.6M
Cap. Flow
-$185M
Cap. Flow %
-13.36%
Top 10 Hldgs %
97.14%
Holding
14
New
1
Increased
2
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$224M
2
DNTH icon
Dianthus Therapeutics
DNTH
+$23.2M
3
ZBIO
Zenas BioPharma
ZBIO
+$3.37M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$129M
2
APGE icon
Apogee Therapeutics
APGE
+$127M
3
NUVL
Nuvalent
NUVL
+$73.2M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$54.4M
5
ELVN icon
Enliven Therapeutics
ELVN
+$51.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q1 2026 Portfolio in Review

As of Q1 2026, Fairmount Funds Management held 14 positions worth $1.38B, up 5.4% from $1.31B the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Fairmount Funds Management withdrew a net $185M in Q1 2026, closing 2 positions and reducing 3 holdings. Its most notable exit was Nuvalent, an estimated $73.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Fairmount Funds Management opened a new position in Damora Therapeutics, Inc. Ordinary Shares worth $226M.

  • Fairmount Funds Management's largest Q1 2026 buy was Damora Therapeutics, Inc. Ordinary Shares: 8,713,000 shares worth $226M.
  • Fairmount Funds Management added most to Dianthus Therapeutics in Q1 2026, an estimated $23.2M increase.
  • Fairmount Funds Management's biggest Q1 2026 reduction was Cogent Biosciences, cutting an estimated $129M.
  • Fairmount Funds Management fully exited Nuvalent in Q1 2026, selling an estimated $73.2M.
  • Fairmount Funds Management's ten largest holdings make up 97% of its $1.38B portfolio in Q1 2026.
  • Fairmount Funds Management opened 1 new position and closed 2 in Q1 2026.
  • Fairmount Funds Management's portfolio value rose 5.4% quarter-over-quarter to $1.38B.

Based on Fairmount Funds Management's 13F filing for Q1 2026, filed 15 May 2026.